297 related articles for article (PubMed ID: 27542119)
21. Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study.
Yao P; Gao Q; Wang Y; Yao Q; Zhang J
ChemMedChem; 2021 Jun; 16(12):1933-1944. PubMed ID: 33686739
[TBL] [Abstract][Full Text] [Related]
22. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors.
Xiang Y; Hou Z; Zhang Z
Chem Biol Drug Des; 2012 May; 79(5):760-70. PubMed ID: 22268420
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Kashyap K; Kakkar R
Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
[TBL] [Abstract][Full Text] [Related]
25. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
Abdizadeh T; Ghodsi R; Hadizadeh F
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791
[TBL] [Abstract][Full Text] [Related]
27. Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors.
Sirous H; Campiani G; Brogi S; Calderone V; Chemi G
Molecules; 2020 Apr; 25(8):. PubMed ID: 32331470
[TBL] [Abstract][Full Text] [Related]
28. Quantitative structure-activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries.
Pham-The H; Casañola-Martin G; Diéguez-Santana K; Nguyen-Hai N; Ngoc NT; Vu-Duc L; Le-Thi-Thu H
SAR QSAR Environ Res; 2017 Mar; 28(3):199-220. PubMed ID: 28332438
[TBL] [Abstract][Full Text] [Related]
29. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
30. Common SAR Derived from Multiple QSAR Models on Vorinostat Derivatives Targeting HDACs in Tumor Treatment.
Praseetha S; Bandaru S; Yadav M; Nayarisseri A; Sureshkumar S
Curr Pharm Des; 2016; 22(33):5072-5078. PubMed ID: 27339433
[TBL] [Abstract][Full Text] [Related]
31. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
32. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
Banerjee S; Baidya SK; Adhikari N; Jha T
SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
[TBL] [Abstract][Full Text] [Related]
33. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
34. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
[TBL] [Abstract][Full Text] [Related]
35. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
[TBL] [Abstract][Full Text] [Related]
36. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
[TBL] [Abstract][Full Text] [Related]
37. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
38. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Banerjee S; Adhikari N; Amin SA; Jha T
J Biomol Struct Dyn; 2020 Mar; 38(5):1551-1564. PubMed ID: 31074329
[TBL] [Abstract][Full Text] [Related]
39. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8.
Kulandaivelu U; Chilakamari LM; Jadav SS; Rao TR; Jayaveera KN; Shireesha B; Hauser AT; Senger J; Marek M; Romier C; Jung M; Jayaprakash V
Bioorg Chem; 2014 Dec; 57():116-120. PubMed ID: 25462986
[TBL] [Abstract][Full Text] [Related]
40. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Patel P; Patel VK; Singh A; Jawaid T; Kamal M; Rajak H
Curr Comput Aided Drug Des; 2019; 15(2):145-166. PubMed ID: 29732991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
